ImmunogenX

ImmunogenX® is a clinical-stage biotherapeutics company established in 2013, dedicated to advancing celiac disease management. Their flagship product, Latiglutenase, shows promise in revolutionizing the treatment of celiac disease. Supported by leading experts in celiac disease research, ImmunogenX is also developing CypCel™, a minimally-invasive diagnostic tool to monitor celiac disease management. This innovative tool will utilize a clinically meaningful metabolic marker to assess the recovery status of patients undergoing gluten-free diets or other treatments. In addition to therapeutics and diagnostics, ImmunogenX is working on enhancing food safety by employing advanced mass spectrometry techniques to detect and quantify critical gluten peptide sequences found in wheat, barley, and rye. The most recent investment in ImmunogenX was a grant investment received on 11 April 2019 from the National Institute of Allergy and Infectious Diseases. As a company operating within the Biotechnology and Health Care industries, ImmunogenX is positioned at the forefront of advancing celiac disease treatment and diagnosis. Their commitment to innovation in therapy, diagnostics, and food safety for celiac patients makes them a noteworthy player in the biotech landscape.